Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 14645233
Prasad A, Fernandis AZ, Rao Y, Ganju RK (2004) Slit protein-mediated inhibition of CXCR4-induced chemotactic and chemoinvasive signaling pathways in breast cancer cells. J Biol Chem 279, 9115-24 14645233
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  DU4475 (breast cell)
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CXCL12 increase
Slit CXCL12 inhibit treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  DU4475 (breast cell)
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CXCL12 increase
Slit CXCL12 inhibit treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  DU4475 (breast cell)
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CXCL12 increase
Slit CXCL12 inhibit treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  DU4475 (breast cell)
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CXCL12 increase
Slit CXCL12 inhibit treatment-induced increase

Y576-p - FAK (human)
Modsite: RyMEDstyyKAsKGK SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y576‑p, FAK iso2 (human): Y424‑p, FAK iso5 (human): Y576‑p, FAK (mouse): Y576‑p, FAK iso2 (mouse): Y607‑p, FAK iso4 (mouse): Y576‑p, FAK iso9 (mouse): , FAK (rat): Y576‑p, FAK (chicken): Y576‑p, FAK iso5 (chicken):
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  DU4475 (breast cell)
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CXCL12 increase
Slit CXCL12 inhibit treatment-induced increase

Y580-p - Pyk2 (human)
Modsite: yIEDEDyykAsVTRL SwissProt Entrez-Gene
Orthologous residues
Pyk2 (human): Y580‑p, Pyk2 iso2 (human): Y580‑p, Pyk2 (mouse): Y580‑p, Pyk2 (rat): Y580‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  DU4475 (breast cell)
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CXCL12 increase
Slit CXCL12 inhibit treatment-induced increase

Y881-p - Pyk2 (human)
Modsite: DRTDDLVyLNVMELV SwissProt Entrez-Gene
Orthologous residues
Pyk2 (human): Y881‑p, Pyk2 iso2 (human): Y839‑p, Pyk2 (mouse): Y881‑p, Pyk2 (rat): Y881‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  DU4475 (breast cell)
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CXCL12 increase
Slit CXCL12 inhibit treatment-induced increase